Literature DB >> 29513108

Hereditary angioedema due to C1-inhibitor deficiency in Macedonia: clinical characteristics, novel SERPING1 mutations and genetic factors modifying the clinical phenotype.

Vesna Grivčeva-Panovska1, Mitja Košnik2,3, Peter Korošec2, Slađana Andrejević4, Ljerka Karadža-Lapić5, Matija Rijavec2.   

Abstract

OBJECTIVE: Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a rare disease, characterized by swellings. We aimed to characterize on a clinical and molecular basis C1-INH-HAE patients in the Republic of Macedonia.
RESULTS: All 15 patients from six unrelated families were diagnosed with C1-INH-HAE type I, with a mean age of symptom onset of 11 years and an average delay of diagnosis of seven years. Patients reported on average 31 angioedema attacks/year, with a median clinical severity score (CSS) of 7. We identified three known mutations and two new mutations (c.813_818delCAACAA and c.1488T > G) that were reported for the first time. To address the genotype-phenotype association, a pooled analysis including 78 C1-INH-HAE south-eastern European patients was performed, with additional analysis of F12-46C/T and KLKB1-428G/A polymorphisms. We demonstrated that patients with nonsense and frameshift mutations, large deletions/insertions, splicing defects and mutations at Arg444 exhibited an increased CSS compared with missense mutations, excluding mutations at Arg444. In addition, the CC F12-46C/T polymorphism was suggestive of earlier disease onset. DISCUSSION: Genetic analysis helped identify the molecular basis of C1-INH-HAE given that causative mutations in SERPING1 were detected in all patients, including an infant before the appearance of clinical symptoms. We identified two novel mutations and further corroborated the genotype-phenotype relationship, wherein mutations with a clear effect on C1-INH function predispose patients to a more severe disease phenotype and CC F12-46C/T predisposes patients to earlier disease onset. KEY MESSAGES • In the present nationwide study, we aimed to characterize on a clinical and molecular basis patients with hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) in the Republic of Macedonia.   • Causative mutations in SERPING1 were detected in all 15 C1-INH-HAE patients from six Macedonian families, including an infant, before the appearance of clinical symptoms.   • We identified three known mutations and two novel mutations (c.813_818delCAACAA and c.1488T > G). These findings further corroborated the genotype-phenotype relationship, wherein mutations with a clear effect on C1-INH function predispose patients to a more severe disease phenotype and the CC F12-46C/T polymorphism predisposes patients to earlier disease onset.

Entities:  

Keywords:  C1 inhibitor; Hereditary angioedema; Macedonia; SERPING1 gene

Mesh:

Substances:

Year:  2018        PMID: 29513108     DOI: 10.1080/07853890.2018.1449959

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  4 in total

Review 1.  Leveraging Genetics for Hereditary Angioedema: A Road Map to Precision Medicine.

Authors:  Anastasios E Germenis; Matija Rijavec; Camila Lopes Veronez
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-28       Impact factor: 8.667

2.  In Search of an Association Between Genotype and Phenotype in Hereditary Angioedema due to C1-INH Deficiency.

Authors:  David Loli-Ausejo; Alberto López-Lera; Christian Drouet; Marina Lluncor; Elsa Phillips-Anglés; María Pedrosa; Rosario Cabañas; Teresa Caballero
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-19       Impact factor: 8.667

Review 3.  The Genetics of Hereditary Angioedema: A Review.

Authors:  Rosa Santacroce; Giovanna D'Andrea; Angela Bruna Maffione; Maurizio Margaglione; Maria d'Apolito
Journal:  J Clin Med       Date:  2021-05-09       Impact factor: 4.241

Review 4.  Biomarkers in Hereditary Angioedema.

Authors:  Grzegorz Porebski; Mateusz Kwitniewski; Avner Reshef
Journal:  Clin Rev Allergy Immunol       Date:  2021-02-09       Impact factor: 8.667

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.